Impact of Reimbursement for Biomarker Testing on Clinical PracticeVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Dr Wainberg and Dr Gerson talk about blocking cancer stem cell pathways and how randomized trials using therapies aimed at these pathways.
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.